Citadel Advisors
BLRX

Citadel Advisors’s BioLineRX BLRX Stock Holding History

Citadel Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9K Buy
+14,796
New +$42.9K ﹤0.01% 13156
2026
Q1 		– Sell
-36,651
Closed -$104K – 13013
2025
Q4 		$104K Buy
36,651
+26,631
+266% +$92K ﹤0.01% 11605
2025
Q3 		$37.9K Sell
10,020
-4,934
-33% -$19.8K ﹤0.01% 12318
2025
Q2 		$68.3K Buy
+14,954
New +$55.3K ﹤0.01% 11608
2025
Q1 		– Sell
-383
Closed -$3.25K – 14505
2024
Q4 		$3.25K Buy
+383
New +$5.65K ﹤0.01% 14010
2024
Q1 		– Sell
-605
Closed -$30.3K – 14577
2023
Q4 		$38K Sell
605
-869
-59% -$53.8K ﹤0.01% 12057
2023
Q3 		$107K Sell
1,474
-3,845
-72% -$258K ﹤0.01% 10815
2023
Q2 		$339K Buy
+5,319
New +$295K ﹤0.01% 8772
2022
Q3 		– Sell
-569
Closed -$29K – 12631
2022
Q2 		$29K Buy
+569
New +$31.6K ﹤0.01% 12240
2021
Q4 		– Sell
-4,129
Closed -$430K – 13814
2021
Q3 		$451K Buy
4,129
+3,002
+266% +$356K ﹤0.01% 10127
2021
Q2 		$127K Buy
+1,127
New +$132K ﹤0.01% 12683
2021
Q1 		– Sell
-1,233
Closed -$124K – 13162
2020
Q4 		$124K Buy
+1,233
New +$108K ﹤0.01% 10078
2019
Q2 		– Sell
-56
Closed -$14K – 9174
2019
Q1 		$14K Sell
56
-41
-42% -$11.9K ﹤0.01% 9119
2018
Q4 		$26K Buy
+97
New +$46.7K ﹤0.01% 8660
2018
Q2 		– Sell
-22
Closed -$11K – 8822
2018
Q1 		$11K Sell
22
-14
-39% -$8.58K ﹤0.01% 8175
2017
Q4 		$24K Buy
36
+17
+89% +$11.2K ﹤0.01% 7800
2017
Q3 		$13K Buy
+19
New +$11.8K ﹤0.01% 7423
2017
Q2 		– Sell
-177
Closed -$102K – 7483
2017
Q1 		$102K Buy
177
+144
+436% +$92.7K ﹤0.01% 6854
2016
Q4 		$18K Buy
33
+6
+22% +$3.73K ﹤0.01% 7102
2016
Q3 		$19K Buy
+27
New +$14.4K ﹤0.01% 7063
2014
Q2 		– Sell
-54
Closed -$72K – 7963
2014
Q1 		$72K Buy
+54
New +$88.8K ﹤0.01% 6472

Other funds holding BLRX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Citadel Advisors's BLRX Position: Q2 2026 in Review

Citadel Advisors opened a new position in BioLineRX (BLRX) in Q2 2026: 14,796 shares worth $45.9K. The stake represents ﹤0.01% of the portfolio and ranks #13156 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BLRX as recently as Q4 2025.

Citadel Advisors first reported a position in BLRX in Q1 2014 and has held it in 21 quarters since. The position peaked at $451K in Q3 2021. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • Citadel Advisors held 14,796 shares of BioLineRX worth $45.9K as of Q2 2026.
  • BioLineRX was a new Citadel Advisors position in Q2 2026.
  • BioLineRX made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13156 holding.
  • Citadel Advisors first reported a position in BioLineRX in Q1 2014 and has held it in 21 quarters since.
  • Citadel Advisors's BioLineRX position peaked at $451K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.